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Problem: Osteomyelitis is a major infection that destroys bone. Treatment of the 
infection involves use of an injectable calcium sulfate material. This material may be 
used for the local delivery of antibiotics at the site of infection to improve clinical 
treatment. Studies are needed to determine effects of added antibiotics on injectable 
calcium sulfate material properties. 
Hypothesis: Antibiotic-loaded injectable calcium sulfate will retain their 
chemical/mechanical properties, and elution of the antibiotics will remain large enough to 
inhibit any microbial infections. 
Aims: 
1. Characterize effects of mixing amphotericin B, cefazolin, or vancomycin on 
calcium sulfate’s properties. 
2. Measure elution/dissolution profiles in vitro. 
3. Evaluate eluents ability to inhibit bacterial growth. 
Conclusion: There were no adverse effects on the material’s characteristics. Cefazolin 
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Chapter I: Introduction & Specific Aims 
Problem Statement 
Osteomyelitis is a major concern in orthopedic surgery. A local drug delivery 
system involving an injectable calcium sulfate may be an efficient way to eliminate 
infections and treat infected orthopedic sites. The advantages of injectable calcium sulfate 
for local drug delivery are that it is bioresorbable, osteoconductive, biocompatible, has a 
mild set temperature, and may be injected percutaneously. Antibiotics that are considered 
by physicians for use in treating osteomyelitis via local delivery with injectable calcium 
sulfates include: cefazolin, levofloxacin, linezolid, piperacillin, daptomycin, vancomycin, 
and ceftriaxone. However, it is not clear how the addition of these antibiotics may affect 
the physical properties important to clinical use of the injectable calcium sulfate materials. 
The overall objective of this work is to evaluate the effects of three antibiotics of interest, 
amphotericin B, cefazolin, and vancomycin, on physical-chemical properties, and to 
determine their release and antimicrobial effects in vitro from a commercial calcium 
sulfate injectable graft material, Minimally Invasive Injectable Graft (MIIG)® X3 
(Wright Medical Technology, Inc., Arlington, TN). In addition, the majority of the 
published data available on the use of antibiotics with calcium sulfate focus on elution of 
the antibiotic from a small pellet (~0.1cc), rather than a bolus as would be seen with an 
injectable product such as MIIG® X3. Hence, this project will also use an injectable 






Aims of this Research 
1. Characterize the effects of mixing one of the three antibiotics, amphotericin B, 
cefazolin, and vancomycin, on physical, chemical, and mechanical properties of 
MIIG® X3. The properties to be evaluated are set time, crystalline phases, 
chemistry, and morphology via Vicat and Gilmore penetration tests, X-Ray 
Diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR), and 
Scanning Election Microscope (SEM), respectively. Diametral Tensile Strength 
(DTS) will also be performed to provide information on mechanical strength. 
2. Measure the in vitro release of the antibiotics from clinically relevant 5cc bolus 
samples of injectable material over 28 days in saline solution using High 
Performance Liquid Chromatography (HPLC) techniques to determine antibiotic 
concentrations in eluent. Also to determine the dissolution of the bolus by change 
in mass during the 28 day elution study. 
3. Evaluate the ability of the released antibiotics to inhibit the in vitro growth of 






Chapter II: Background 
I. Osteomyelitis 
Infection is a major complication in the orthopedic industry. Osteomyelitis is an 
infection caused by invading microorganisms that may destroy bone. Osteomyelitis 
occurs when a bacteria from a simple wound or cut enters blood and infects bone. It may 
also occur from foot ulcers, open fractures, or from surgery that may include an implant. 
Osteomyelitis may be characterized as acute or chronic. Acute osteomyelitis refers to a 
new infection in bone that develops within two weeks of infection.
1
 Common symptoms 
include swelling, fever, pain, chills, and tenderness. If osteomyelitis persists after 4-6 
months even after antibiotic treatment, then it is considered chronic osteomyelitis. 
Chronic osteomyelitis occurs in about 2 in 10,000 adults nationwide, but children have it 
at a rate of about 1 in 5,000.
2
 Infected bone may act as a nidus for infection and spread to 
other tissues including skin, muscles, or even tendons. Any previous or current injuries or 
even surgeries that require an implant like a metal rod/plate to be placed in the bone 
increase susceptibility to developing osteomyelitis infection.
3
 Another problem faced 
with osteomyelitis is the possibility of it spreading through the body through the vascular 
system.
3
 Risk factors that may contribute to infection are: diabetes, hemodialysis for 
patients with kidney complications, poor blood supply, recent injuries, and even patients 
who had a splenectomy.
3
 
A. Infecting Organisms 
Bacteria are usually the common microorganisms to cause myelolytic infections, 




reported among 4 year olds to adults.
3
 Bacteria are split into separate classifications: 
Gram positive or Gram negative. Gram-positive bacteria contain a thick layer of 
peptidoglycan over the cell membrane, as seen in figure 1. The polymer peptidoglycan is 
a combination of sugars and amino acids that creates a mesh-like layer around the 
bacteria’s cell membrane. The most common Gram-positive bacteria found in 
osteomyelitis are Staphylococcus aureus, Staphylococcus epidermis, Streptococcus 
pyogenes, Propionibacterium acnes, and Actinomyces israelii.
1,4
 Gram-negative bacteria 
contain an outer membrane containing lipopolysaccharide and a thin peptidoglycan layer 
over the cell membrane, as seen in Figure 1. Lipopolysaccharide is a large polymer 
composed of lipid and polysaccharide, which acts as an endotoxin within the body 
causing septic shock
5
. Common Gram-negative bacteria that have been reported to cause 
osteomyelitis are: Escherichia coli, Haemophilus influenzae, Serratia marcescens, and 
Pseudomonas aeruginosa.
1,6
 In a clinical study conducted by Meyers, 16 patients 
developed osteomyelitis infected by Gram-negative bacteria, which was approximately 








Figure 1: Schematic of the differences between Gram positive & Gram negative bacteria 




Fungal osteomyelitis has emerged to become more prevalent within the past few 
decades.
9
 These cases are usually most prevalent in people with depressed immune 
systems or diabetic patients with foot ulcers. An estimated 15% or more of diabetic 
patients will have a foot fungal infection that may lead to osteomyelitis.
4
 Fungal 
osteomyelitis may occur as a part of a polymicrobial infection or as an isolated condition. 
It may spread by from an infected tissue, direct contact with fungi in skin flora or diabetic 
ulcers, or via the vascular system as a complication of pulmonary or other type of deep 
internal infection.
10,11








Some bacteria or fungi may attach to bone or an implanted device and begin to 
form a biofilm. Biofilm is the formation of a collection of microorganisms that adhere to 
each other and/or to a surface.
13
 The microorganisms begin to excrete a conglomerate of 
extracellular DNA, proteins, and polysaccharides which is called the extracellular matrix. 
The extracellular matrix helps promote adhesion, provides protection, and facilitates 
communication between the bacterial cells by providing a separate environment from the 
rest of the body. It impedes the entry of antimicrobials into the protected environment 
and is even strong enough to cause biofilms to become fossilized.
13
 Biofilm is difficult to 
treat, since the layer of extracellular matrix provides protection to the underlying bacteria. 
An estimated 80% of all implant infections have biofilm involvement.
14
 If the infection is 
associated with a metal rod/plate or a prosthetic, biofilm formation may lead for the need 
of implant removal.
14
 If the infection develops into a chronic condition, then surgery, 
such as debridement or even amputation, may be needed to prevent spread of infection 
through body, especially in diabetics or patients with poor blood supply.
1,15,16 
B. Treatment of Osteomyelitis 
Several treatments for osteomyelitis infection include systemic antibiotics, 
surgical debridement with/without antibiotics, local drug delivery systems, and 
amputation or removal of implant.
4
 One or more treatment methods may be combined to 
combat osteomyelitic infection. Systemic antibiotics may be administered for up to a 
month, with some treatments lasting up to 42 days.
16




be successful for acute osteomyelitis, but this treatment approach will not usually work 
with patients with chronic osteomyelitis or diabetic patient due to local damage to the 
vascular system.
16
 Surgical debridement is the next course of action and requires removal 
of a patient's dead, damaged, or infected tissue. This approach helps prevent the 
remaining healthy tissue from becoming infected and also allows bone and soft tissue to 
begin new tissue formation.
17
 Even if osteomyelitis is treated with systemic antibiotics, 
surgery may be required to remove dead tissue or an abscess left behind after treatment. 
Debridement removes the infection, but it is painful for the patient and incisions may 
generate new infections.
17
 If a resulting void is produced after surgery, it may be packed 
with a bone graft, such as calcium sulfate or calcium phosphate, that promotes the growth 
of new bone tissue or bone filler. Bone graft and bone filler materials have been used 
successfully for locally delivering antibiotics to treat osteomyelitis.
17-27
 If all treatments 
fail, amputation or implant removal becomes the patient’s last resort. 
II. Local Drug Delivery 
Challenges in systemic treatments of osteomyelitis or in preventing re-infection in 
bone are delivering the antibiotic to the site at an effective concentration and for duration 
to abate the infecting agents. Complications arise due to the relatively poor or 
compromised blood supply and the nature of the biofilm itself.
16
 Local drug delivery 
systems may help prevent or combat infection by overcoming limits of systemic delivery, 
such as adverse immune response from a high antibiotic concentration.
16
 The advantages 
of local delivery are that this treatment mostly allows antibiotics to be delivered directly 
to the site of infection more efficiently and at higher doses than systemic delivery.
16
 This 




circulation, such as cartilage or bone.
16
 Drug compliance issues that physicians encounter 
with patients are eliminated.
16
 Drug compliance issues include whether a patient is taking 
the medication, whether they are taking the correct amount, and whether they complete 
the course of the medication to insure infection is gone. 
Local drug delivery methods used to treat osteomyelitis are antibiotic-loaded 
PMMA, calcium sulfate, calcium phosphate, and synthetic and natural polymers. The 
ideal local drug delivery system for osteomyelitis would be one that is able to release a 
high concentration of antibiotic to abate infection and subsequently a gradual declining 
concentration to avoid inducing antibiotic resistance, be osteoconductive, biocompatible, 
and bioresorbable, and be able to have some functional strength.
17-27
 The material may 
encounter mechanical stresses from the patient moving, especially if the material is being 
used to hold an implant in place.
31,47
 Calcium sulfate and calcium phosphate are 
resorbable and biocompatible material, therefore the dissolving ions may combine within 
body fluids and not elicit an immune response.
29
 In most cases, osteoconductivity is 
promoted while the biomaterial is resorbing. The optimal antibiotic release profile is an 
initial burst release to combat the onset of infection directly after surgery and then a 





The addition of antibiotics to PMMA was one of the earliest types of local drug 
delivery systems. The advantage of PMMA is that it has a very slow and prolonged 




and must be removed from the body.
29,30 
If it is not removed, there is always the 
possibility of a biofilm forming on the surface of the material, which may cause the 
infection to be harder to treat. Antibiotic-loaded PMMA is usually made by adding 
antibiotic to the mixture of PMMA powder and monomer solution and then spreading 
material over a polymer mold plate to form beads. PMMA beads are packed into bone 
voids, especially ones created after debridement. PMMA may also be used as bone 
cement in revision orthopedic surgery, such as the Prostalac® hip offered by DePuy 
(Warsaw, IN).
31
 Studies have been shown that antibiotics are only eluted from the outer 
surface area and the remaining antibiotic may be sequestered inside the bead for up to 10 
years due to the PMMA’s less porous surface characteristics.
32
 PMMA beads typically 
require removal due to their limited elution profile and their presence as a foreign body.   




B. Collagen, Chitosan, Synthetic Polymers, & DBM 
Collagen and chitosan have both been used to deliver antibiotics, but they often 
require chemical modification to control degradation rates.
30,34,35
 Their biocompatible and 
bioresorbable characteristics make them appealing for local drug delivery, but both are 
usually used as hemostats to control bleeding and cannot endure mechanical stresses that 
bone cements do.
36
  Synthetic polymers, such as polyglycolic acid and polylactic acid, are 
usually not as popular in local drug delivery, because of their characteristics to elicit an 
inflammatory response when they begin to degrade due to acidic degradation products.
37
 
Demineralized bone matrix (DBM) is also another possible bone graft material suitable 




Wright Medical offers a product called Allomatrix® Injectable Putty that contains 86% 
by volume of DBM, while the rest is cancellous bone chips. In a study conducted by 
Lewis et. al, Gentamicin was loaded into DBM and the amount of antibiotic released or 
eluted in saline solution was measured.
38
 They reported that the levels of antibiotic 
released were high enough to inhibit S. aureus for at least 13 days in vitro. They also 
determined that the antibiotic had no adverse effects in vitro on the osteoinductive nature 
of the DBM. A disadvantage of DBM is that it is dead bone and may act as another site 
for the osteomyelitic infection to spread when placed into a previously infected site. 
C. Calcium Phosphate/Hydroxyapatite 
There have been many studies and reviews of calcium phosphate materials being 
used as local drug delivery systems.
18-21,39,40
 Advantages of calcium phosphate are its 
biocompatible and resorbable characteristics when implanted in the body. Calcium 
phosphate may be made injectable by combining with sterile water, which is a great 
characteristic for use in minimally invasive surgery and in the treatment of difficult 
accessible sites. In the study conducted by Shinto et al, each porous hydroxyapatite block 
was successfully made by mixing the powder with 75mg of one of the following 
antibiotics: gentamicin, cefoperazone, or fiomoxef.
18
 The antibiotic concentrations 
released were effective in inhibiting S. aureus in vitro for as long as 12 weeks. Calcium 
phosphate may be made to have a highly microporous structure that allows incorporation 
of many types of drugs and biologically active molecules such as growth factors, anti-
inflammatory and anti-cancer drugs, without losing activity and denaturalization.
18,20,21
 
Calcium phosphate is not always porous and does have its disadvantages. It does not have 




time, unless modified to resorb quicker. The long dissolution time with no or reduced 
antibiotic release may allow biofilm formation on the surface of the material and promote 
microbial proliferation.
20,24 
D. Calcium Sulfate in Local Drug Delivery 
Calcium sulfate has been used as bone void filler for over 100 years. Calcium 
sulfate was first used for antibiotic delivery in the 1950’s, with studies showing that it 
may resorb and promote bone growth.
41,42
 It has become increasingly popular for drug 
delivery and has seen a higher rate of use with many antibiotics as compared to calcium 
phosphate, PMMA, collagen, and chitosan.
20
 Biocompatible, biodegradable, 
osteoconductive properties, and similar mechanical strengths as bone are all reasons 
calcium sulfate is used. For local drug delivery, calcium sulfate is selected for 
injectability and low setting temperature that allow incorporation of drugs without the 
potential of denaturing as may occur with PMMA.
20
 
a. History of Calcium Sulfate 
Calcium sulfate is a very common compound and often found in laboratory or 
industrial environments. Calcium sulfate is not only used in the medical industry, but also 
in the baking industry, brewing industry, and pharmaceutical applications, such as dietary 
calcium supplements.
43
 The material may also be used as a desiccant in its anhydrous 
state, called γ-anhydrite, or as a moisture indicator, called Drierite.
44 
Naturally, calcium 
sulfate is a translucent, crystalline white rock and may be found at many locations 
worldwide, especially in Paris where it derives one its names, plaster of Paris. Calcium 




phosphoric acid from phosphate rock, production of hydrogen fluoride, and refining of 
zinc.
44
 World production of natural gypsum, calcium sulfate’s most stable form, is around 
127 million tons per annum.
45
 It was believed to have been discovered as far back as 975 
A.D. by a Persian pharmacist.
46
 
Calcium sulfate hemihydrate (CaSO4·½H2O) will convert to calcium sulfate 
dihydrate (CaSO4·2H2O) when mixed with water by the following weak to moderate 
exothermic chemical reaction: CaSO4·½H2O + 1½ H2O → CaSO4·2H2O.
44,47
 The 
exothermic reaction allows the larger crystals to interlock and harden, creating a melting 
point of 1450 °C.
45
 The hemihydrate (plaster of Paris) will become a dihydrate 
(gypsum/terra alba), which is a hard, cement-like material. Hemihydrate comes in 2 
forms: α-hemihydrate, found in medical applications and β-hemihydrate, found in 
commercial applications.
48
 β–hemihydrate requires more water for hydration and 
therefore will former a stronger structure, but not in medical uses.
48
 Gypsum has a 
naturally occurring anhydrous form called β-anhydrite and may be heated to de-hydrate it 
back to hemihydrate; the process is also called calcination. 
b. Previous Studies with Antibiotic-loaded Calcium Sulfate 
Many research and clinical studies evaluating calcium sulfate for local delivery of 
antibiotics such as gentamicin, amikacin, tobramycin, and daptomycin to treat 
osteomyelitis are available.
22-27,30,48,49
 Miclau et al. compared the release of tobramycin 
from calcium phosphate, calcium sulfate, DBM, and PMMA using 6x4 mm pellets.
49
 
Calcium phosphate and DBM eluted 70% and 45% respectively of their antibiotics by 24 




elution rates of 17% and 7% respectively at 24 hours and trace amounts at 2 to 3 weeks. 
They concluded that calcium phosphate and DBM were good carriers for brief antibiotic 
coverage, such as for open fractures, while calcium sulfate and PMMA were better for 
long term coverage, such as osteomyelitis. 
Nelson et al. used New Zealand white rabbits infected with S. aureus and 
demonstrated that tobramycin-loaded calcium sulfate pellets abated 85% of infection than 
rabbits treated with debridement only (42%), placebo pellets and intramuscular injected 
tobramycin (36%), or placebo pellets (23%).
50 
This study concluded that calcium sulfate 
has potential utility as a biodegradable local antibiotic delivery system in the treatment of 
musculoskeletal infections. 
Wright Medical Technology offers a pre-formed calcium sulfate pellet product, 
OSTEOSET® T that incorporates the antibiotic tobramycin sulfate into the material.
47
 
This product is not approved for market in the United States.
47
 Tobramycin sulfate is in 
the aminoglycoside family of antibiotics, and is very useful in treating Gram-negative 
bacterial infections and S. aureus and S. epidermis.
47
 The success of local delivery 
through the use of calcium sulfate in products such as OSTEOSET® T  has helped stir 
interest in other calcium sulfate products with different types of antibiotics, but effects of 
mixing antibiotics with calcium sulfate on properties of the calcium sulfate are not 
always well documented.
 
Webb et. al reported that setting characteristics of calcium sulfate may be affected 
by the addition of an antibiotic.
30
 In their study, daptomycin (CUBICIN®), a new 




calcium sulfate from setting unless an accelerant, potassium sulfate was added. The 
chemical composition of daptomycin inhibited the conversion of hemihydrate to 
dihydrate, until potassium sulfate was added. Once potassium sulfate was added, the 
antibiotic was eluted as expected, with a large initial release on day 1 and gradual 
decrease over the next 28 days. The daptomycin-loaded pellets also dissolved more 
quickly than tobramycin-loaded pellets. They also determined that the eluents from the 
drug loaded pellets were still able to inhibit S. aureus and S. epidermis growth in vitro. 
A study by Doadrio et al. conducted XRD and FTIR tests on their cephalexin-
loaded calcium sulfate pellets and concluded that the presence of the drug had no effect 
on the physical-chemical behavior of the bone grafts nor affected structural changes to 
the pellets.
25
 While they noted no effect of drug on some properties of the calcium sulfate, 
they did not determine release or bioactivity of the drug. Cephalexin is a cephalosporin 
antibiotic that is in the same class of antibiotic as cefazolin with very similar structures 
and mechanisms of action.  
There are studies conducted on cefazolin and vancomycin-loaded calcium sulfate 
in the pellet form.
22-27
 A study by Jackson et. al demonstrated that vancomycin loaded 
into rapidly resorbing calcium sulfate pellets did have a higher antibiotic release profile 
when compared to amikacin and gentamicin.
48
 In this study, they developed a pellet that 
may fully dissolve within 24 hours. Amikacin and gentamicin pellets fully dissolved and 
eluted antibiotic within 12 hours, while vancomycin pellets released antibiotic out to 24 
hours. Vancomycin had a spike in release at 1 hour and then another burst at 4 and 8 
hours and then slowly decreased until it dissolved. They contributed the slower release to 




Heijink et al. conducted an in vitro study where they were able to retrieve 39% of 
their vancomycin from OSTEOSET®, a calcium sulfate product also offered by Wright 
Medical.
24
 In the study, they also mixed vancomycin with DBX®, an allograft bone void 
filler made by Synthes® (West Chester, PA), and Collagraft®, a synthetic bone graft 
comprised of bovine collagen and hydroxyapatite/tricalcium phosphate (HA/TCP) 
granules that is made by Zimmer® (Warsaw, IN). They were only able to retrieve 9% and 
23%, respectively, of the vancomycin, which further supports that calcium sulfate may be 
more suitable for local drug delivery applications. 
In a study conducted by Xie et. al, vancomycin-loaded calcium sulfate pellets 
were compared to vancomycin-loaded borate glass.
26
 Borate glass was made by replacing 
the SiO2 in silicate-based bioactive glass with B2O3, Over 65 rabbits were infected by 
percutaneously injecting  methicillin-resistant S. aureus (MRSA) into the medullary 
cavity through the lateral aspect of the proximal tibial metaphysic. Each rabbit received 
treatment by debridement and the void was filled with: nothing (group 1), pure borate 
glass (group 2), vancomycin-loaded calcium sulfate (group 3), and vancomycin-loaded 
borate glass (group 4). The vancomycin-loaded calcium sulfate and borate glass had the 
best inhibition rates against the MRSA with 73.33% and 81.25%, respectively. It was 
observed that the calcium sulfate had fully resorbed and had better bone growth 
compared to the borate glass only being partially reabsorbed. 
Another study done by Udomkusonsri et al. showed that cefazolin-loaded calcium 
sulfate beads had a recovery rate of 93.84% after a 15 day elution study in PBS.
27
 They 
only had a 24.10% recovery rate for cefazolin-loaded PMMA beads. They believed 




Their results demonstrated that calcium sulfate may release antibiotic at a much higher 
concentration and be better in local drug delivery compared to PMMA. They also tested 
in vitro the cefazolin eluents effectiveness against Bacillus subtilis, a Gram-positive 
bacteria. Eluents inhibited the bacteria’s growth successfully and they determined that 
mixing cefazolin with calcium sulfate would not affect cefazolin’s antibacterial activity. 
A study conducted by Edin et al. tested the effects of cefazolin and vancomycin 
on osteoblast-like cells.
23
 They used MG-63 human osteosarcoma cell line and exposed it 
to different concentrations of the antibiotics ranging between 0 to 10,000µg/mL and then 
100 to 1000µg/mL to define cefazolin’s toxic level. They determined that levels of 
1000µg/mL or less for vancomycin and 100µg/mL or less for cefazolin have little or no 
effect on the cells. But concentrations of 10,000µg/mL for vancomycin and cefazolin 
caused cell death. Levels of 200µg/mL for cefazolin did cause significant decrease in cell 
replication. They concluded that vancomycin is less toxic than cefazolin at higher 
concentrations and may be a better antibiotic for local drug delivery. 
III. The Use of an Injectable Calcium Sulfate for Local Antibiotic Delivery 
Injectable bone grafts/cements were developed for percutaneous injection of 
calcium phosphate, PMMA, and calcium sulfate in minimally invasive surgery and in the 
treatment of sites that are difficult to access.
47
 Smaller incisions help keep the risks of 
infection low. Lieberman et al. wrote a review paper discussing the characteristics of 
injectable bone cement during percutaneous vertebroplasty, which is the percutaneous 
injection of PMMA into a collapsed vertebral body.
51
 Kyphoplasty may also be done and 




the vertebrae. New bone cements, such as calcium sulfate or calcium phosphate, are 
being incorporated into surgeries for their good biocompatibility, biomechanical strength 
and stiffness, and radiopacity for the fluoroscopy guided procedures.
51
 
Hesaraki et al. conducted a study where injectable macroporous calcium 
phosphate was mixed with cephalexin.
52
 They used sodium dodecyl sulfate to increase 
porosity in calcium phosphate to help increase injectability and for rapid bone resorption. 
They concluded that addition of the cephalexin caused the material to set slower, 
decreased crystallinity of formed apatite phase, but it did improve injectability. In a study 
conducted by Urban et al., calcium phosphate and calcium sulfate were mixed with sterile 
water to develop an injectable composite bone graft.
40
 The ultimate compressive strength 
and elastic modulus of the composite graft were compared to calcium sulfate pellets and 
normal canine bone. In vivo tests with canine models resulted in a small amount of the 
composite graft remaining after 26 weeks, while none remained for calcium sulfate 
pellets. Ultimate compressive strength and elastic modulus were higher for the composite 
graft compared to calcium sulfate pellets. They determined that the calcium 
sulfate/calcium phosphate composite would be successful in clinical applications that 
required a strong, injectable, slower-resorbing, and biocompatible bone graft substitute. 
Wright Medical Technology (WMT, Arlington, TN) began marketing an 
injectable calcium sulfate bone substitute, Minimally Invasive Injectable Graft (MIIG)® 
X3 in May 2003. MIIG® X3 is an injectable calcium sulfate bone graft substitute that is 
used in filling non-load bearing bone voids and fractures.
47 
The MIIG® X3 kit comes 
with a specially designed vacuum mixing bowl, syringe, and injection needle, shown in 




USP (WFI). Under vacuum pressure, the kit is mixed at a rate of approximately 2 
revolutions/second. The product is percutaneously injected while in the hydrated state, 
and typically sets within 7-10 minutes to provide a strong, rigid structure for implant 
fixture or filling up a bone void.
47
 The material’s ability to be injected into a bone void 
and its quick set time gives it useful characteristics for use in local drug delivery during a 
minimally invasive surgery. When calcium sulfate is injected, it will not have the same 
structure as a pre-made pellet. It will appear more as a bolus; small surface area covering 
a larger volume of calcium sulfate. The evaluation of drug release from a bolus sample is 
a focus of this investigation. While many studies of solid/preformed calcium sulfate 
pellets with antibiotics may be found in literature, few studies can be found on adding 
antibiotics to commercially available injectable calcium sulfate bone graft. 
 
  
Figure 2: A. MIIG® X3 Kit offered by Wright Medical Technology, Inc. 








IV. Antibiotics  
Many antibiotics have been investigated for local delivery using calcium sulfate 
materials.
 22-27,30,48,49
  This investigation will be focused on three antibiotics, amphotericin 
B, cefazolin, and vancomycin. These selected antibiotics represent a variety of antibiotic 
classes and will be evaluated in this preliminary investigation. Selection of these 
antibiotics was also based on ability to manipulate the concentrations as needed for 
mixing directly with commercial injectable calcium sulfate cement. Drug availability, 
prices of the drug, and ability to measure eluents were also considered before choosing. A 
brief background of each of these antibiotics follows. 
A. Amphotericin B 
a. Description 
Amphotericin B is a polyene antifungal that was extracted from Streptomyces 
nodosus, a filamentous bacterium originally found in Venezuela. Some trade names that 
Amphotericin B goes by are: Fungilin, Fungizone, Abelcet, AmBisome, Fungisome, 
Amphocil, and Amphotec.
53
 It derives its name from its amphoteric characteristics, 
meaning it has acidic and basic chemical properties. 
b. Mode of Action 
The mechanism of action for this antifungal is by targeting ergosterol, the main 
component of fungal cell membranes. The antifungal agents forms a transmembrane 







c. Where & Why Used 
This antifungal agent is typically given intravenously to patients with systemic 
fungal infections, but this agent has also been known to work against protozoan 
infections. Amphotericin B is available as a cholesteryl sulfate complex, lipid complex, 




Under no circumstances should a total daily dose of 1.5 mg/kg be exceeded.
54 
Optimal dosage for amphotericin B is unknown due to its toxicity, but for Candidiasis it 
is approximately 0.5-1mg/kg/day, which must be infused over 2-6 hours and vital signs 
of patient must be checked on every 15 minutes during infusion. A test dose of 1mg must 
also be given over 1 hour before any more may be administered.  
e. Adverse/Side Effects 
The problem with Amphotericin B’s mechanism of action is that it also targets 
sterols in human cell membranes, which leads to toxicity for human cells.
54
 Additional 
side effects of amphotericin B  include fevers, chills, headaches, irregular heartbeat, 
nausea and vomiting. Adverse effects are much worse and may lead to multiple organ 
damage if it is not administered properly.
53
 
f. Pertinence to Local Delivery 
The purchased powder form was insoluble in water, but was soluble in a solution 




whether this poor solubility would detract from this antifungal agent being used clinically 
with an injectable calcium sulfate bone graft for local antibiotic delivery. Overall, 
amphotericin B was selected for its proper antifungal characteristics. 
B. Cefazolin 
a. Description 
Cefazolin is a cephalosporin antibiotic, which is a class of β-lactam antibiotics. β-
lactam antibiotics contain a nucleus composed of a lactam with a heteroatomic ring 
structure, consisting of 2 carbon and 1 nitrogen atoms.
56
 Cefazolin is often sold under the 
names: Ancef, Cefacidal, Faxilen, Novaporin, Reflin, Zinol, and Kefol. 
b. Mode of Action 
The antibacterial works by disrupting the synthesis of the peptidoglycan layer of 
bacterial cell walls.
57
 β-lactam antibiotics bind to a site where penicillin-binding proteins 
(PBPs) are required to facilitate synthesis of peptidoglycan. Antibacterial agents mimics 




c. Where & Why Used 
The drug is administered by either intramuscular or intravenous injection. 
Cefazolin is effective against mostly Gram-positive bacteria such as staphylococci and 
streptococci bacteria, and is also effective against the Gram-negative bacteria Escherichia 
coli. The antibacterial is mostly used to treat skin infections, but may also be used to treat 





Dosage is based on moderate to severe infections is usually around 500mg-1g 
every 6 to 8 hours orally and may go above 1g doses if infection is life-threatening.
57 
e. Adverse/Side Effects 
Adverse effects for cefazolin are very rare, but possible side effects are usually 
stomach aches, diarrhea, or vomiting.
58 
f. Pertinence to Local Delivery 
Cefazolin was selected, because it is a β-lactam antibiotic and its mechanism of 
action help fight off E. coli and S. aureus, who are major players in osteomyelitis. 
C. Vancomycin 
a. Description 
Vancomycin (sold as Vancocin, (manufacturer), or COVANC, (manufacturer) is a 
glycopeptide antibiotic, which is a class composed of glycosylated cyclic or polycyclic 
nonribosomal peptides. The antibacterial was isolated from the bacteria Amycolatopsis 
orientalis from the jungles of Borneo.
59 
b. Mode of Action 
Like cefazolin, vancomycin inhibits the synthesis of the bacterial peptidoglycan 
layer; however, the mechanism for this inhibition is different.
60 
The antibiotic prevents N-
acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) subunits from combining 





c. Where & why used 
Vancomycin is effective against Gram-positive bacteria, especially S. aureus, but 
is not effective against Gram-negative bacteria. The antibacterial is administered orally 
for colon infections and intravenous injections for systemic infection. Vancomycin is 
only used in the line of last defense in serious, life-threatening infections, due to its high 
potential for toxicity in the body and for increased antibiotic resistance which has 
developed to more common antibiotics.
61
 Vancomycin is usually effective against 
bacteria resistant to penicillins, such as methicillin-resistant S. aureus (MRSA), and is 
also useful for patients with allergies to penicillins. 
d. Dosage 
Intravenous dosages are 2 g divided either as 500 mg every 6 hours or 1 g every 
12 hours. Each dose should be administered at no more than 10 mg/min.
60
 
e. Adverse/Side Effects 
Side effects may range from hearing loss, fever, chills, fainting, skin rash, 
diarrhea, and nausea. Adverse effects include nephrotoxicity and ototoxicity; therefore, 
the drug must be administered carefully.
59
 
f. Pertinence to Local Delivery 
There has been an increased amount of vancomycin-resistant bacteria, which has 
caused serious concern in health officials.
62
 Vancomycin was chosen for its effectiveness 





Chapter III: Hypothesis 
The overall objective of this study is to evaluate the potential from injectable 
calcium sulfate bone graft to be used as a local drug delivery system for the antibiotics 
amphotericin B, cefazolin, and vancomycin. In this study, mechanical and physical-
chemical properties of the antibiotic-loaded calcium sulfate bolus will be evaluated and 
antibiotic release and activity against model bacteria determined. The specific hypot of 
this study is that calcium sulfate bone graft retains its physical-chemical and mechanical 
properties when mixed with antibiotics. For up to 28 days, elution of the antibiotics will 
remain above the minimum inhibition concentration (MIC) and will inhibit any microbial 
infections. The larger bolus will not dissolve completely and will release antibiotic till the 





Chapter IV: Materials & Methods 
In this investigation, the commercially available injectable calcium sulfate bone 
graft, Minimally Invasive Injectable Graft (MIIG)® X3, from Wright Medical 
Technology (Arlington, TN) was evaluated as a local antibiotic drug delivery mechanism. 
This material was selected because of availability and current use clinically, its ability to 
be injected percutaneously in its hydrated state and would typically set within 7-10 
minutes. The antibiotics, cefazolin, vancomycin, and amphotericin B, were selected for 
evaluation for delivery from the MIIG® X3 product because of their antimicrobial effect 
on common pathogens that may cause osteomyelitis. The effects of adding the antibiotics 
on the physical properties of the MIIG® X3 product will be evaluated since effects are 
not well documented. The parameters investigated included set-time via Vicat/Gilmore 
penetration tests, Calcium Sulfate conversion via X-Ray Diffraction (XRD), chemical 
structure via Fourier Transform infrared Spectroscopy (FTIR), surface characteristics via 
Scanning Electron Microscopy (SEM), and mechanical properties via Diametral Tensile 
Strength (DTS) testing. The release and activity of the eluted antibiotics over 28 days, 
which is commonly used, was also evaluated via High Performance Liquid 
Chromatography (HPLC) and bacterial growth inhibition in turbidity assays respectively. 
In the experiment, replicate samples (n=5) of MIIG® X3 for each antibiotic were made 
from individual kits.  Replicate samples (n=5) of MIIG® X3 made from individual kits 






I. Mixing MIIG® X3 with Antibiotic 
An antibiotic dosage of 1g of cefazolin, 1g of vancomycin, or 50mg of 
amphotericin B was added to 35g of calcium sulfate in the 15cc MIIG® X3 kit resulting 
in mixtures containing ~2.9 weight% of cefazolin or vancomycin, or ~0.14 weight% of 
amphotericin B based on calcium sulfate powder. The chosen dosage was based on 
clinically relevant amounts that may be safely administered to patients.
54
 The dose of 




The antibiotics came in a powder form and were reconstituted in 4mL of water for 
Irrigation, USP (WFI). After the antibiotic had dissolved in the WFI, the calcium sulfate 
powder was added and mixed at a rate of 70 revolutions in 30 seconds in the supplied 
mixer from the kit (84XS-0405: mini MIIG® X3 High Strength Injectable Graft and 
84XS-0415: MIIG® X3 High Strength Injectable Graft). Cefazolin and vancomycin fully 
dissolved in the WFI and were used immediately to prepare the calcium sulfate cement. 
Because of the previously discussed poor solubility of the amphotericin B, mixing in WFI 
was extended to 3 minutes prior to mixing with calcium sulfate powder. Methanol or 
dimethyl sulfoxide was not used as solvents, since it would have not been clinically 
relevant. Immediately after mixing each batch, a sample was taken for evaluation of set 
time. Each batch was further divided in to samples for XRD, SEM and FTIR testing. 
II. Set Time Testing 
 The Vicat test, developed per ASTM Standard C472.26  (Standard Test Methods 




PA, USA), is used to determine the set time (minutes) of the bone graft. The test is based 
on the penetration of a 1 mm diameter flat head needle into the cement under a constant 
load (300g); set time is established as the time it takes for the needle to penetrate less 
than half the original distance. Immediately after mixing with or without antibiotic 
solution, approximately 15mL of cement was poured into a 60mm diameter by 15mm tall 
container and then a Buffalo Vibrator (Model # 200) was used to remove air bubbles and 
create a flat surface. Samples were tested using the same bolus volume of 15mL of mixed 
cement and penetration measurements were performed at 30 second time intervals until 
the material set. Testing began to lose its surface gloss and was repeated at 30 second 
time intervals until the material set as described through needle penetration. The needle 
was cleaned and a new test location used each time. If the needle fell less than half the 
original distance it was considered set. Each antibiotic mixture were tested along with a 
control (no antibiotic) with a replicate (n=5) for each configuration. 
The Gilmore test, developed per ASTM Standard C266.89 (Standard Test Method 
for Time of Setting of Hydraulic-Cement Paste by Gilmore Needles vol 04.01, ASTM, 
Inc., PA, USA), was also used to determine the set time of the mixtures. The method is 
very similar to the Vicat test, except for two differences. The first difference was the 
Gilmore apparatus contained 2 stainless steel needles with 4.8mm cylindrical flat-ends: 
Gilmore 1 contains 1.06mm diameter and 113.4g weight for initial set; Gilmore 2 
contains a 2.12mm diameter and 453.6g weight for final set. The second difference is the 






III. Calcium Sulfate Conversion 
X-Ray Diffraction (XRD) was used to evaluate if any un-reacted or non-
converted material remained after mixing MIIG® X3 with the antibiotic. After mixing for 
initial penetration tests, material was allowed to finish setting for at least 24 hours before 
performing XRD, FTIR, and SEM. Set samples for XRD analysis were crushed using a 
mortar and pestle to make a powder. XRD spectra were obtained using a Bruker D8 
Advance X-Ray Diffractometer. The scan range for 2Θ was set to approximately 10 to 60° 
to ensure all peaks were captured. Peaks at 2Θ = 29.1° and 2Θ = 29.7° were associated 
with dihydrate and hemihydrate, respectively. Percentage of hemihydrate and dihydrate 
were calculated by the following equation: 
 
% Hemihydrate or Dihydrate = (intensity of hemihydrate or dihydrate/intensity total 
of both hemihydrate and dihydrate) * 100 
 
 
IV. Chemical Structure 
Fourier Transform Infrared Spectroscopy (FTIR) analysis was used to determine 
the overall composition of the set test mixtures with antibiotics and compared to the 
controls that did not contain any antibiotics. When infrared radiation is passed through a 
sample, light is absorbed while the rest is transmitted. A spectrum is produced that 




fingerprint of the sample. A background reference was collected before each sample run. 
Set samples for FTIR analysis were crushed into a powder using mortar and pestle. The 
powder was placed on a plate that contained a diamond/ZnSe crystal in the center on the 
Standard Sample Holder and compressed. Spectra were collected using a Nicolet iS10 
FTIR Machine (Vernon Hills, IL). 
V. Surface Characteristics 
Surface morphology of the set test and control cement samples was observed 
using a Scanning Election Microscope, SEM (LEO 1450 Variable Pressure Scanning 
Electron Microscope, Clifton Road, England). Images were taken for each type of 
calcium sulfate/antibiotic mixture, including controls for comparison, at various 
magnifications: 1000x, 1500x, and 2500x. Images were analyzed for any differences 
between surface features, such as crystalline form, pores, and crater formation. Also, 
Energy-Dispersive X-Ray Spectroscopy (EDS) was conducted to measure the amount of 
certain elements (carbon, oxygen, calcium, and sulfur) in each sample for the purpose of 
comparing to the control. 
VI. Mechanical Testing 
Diametral Tensile Strength (DTS) test was used to determine whether the 
mechanical strength of MIIG® X3 changed due to the addition of the antibiotics. After 
mixing, MIIG® X3 was injected into a 15mm symmetrical polyurethane foam cube with 
a 10 mm open cylindrical void and allowed to harden under wet or dry conditions. For 
wet conditions, samples were allowed to cure in bovine calf serum at 37°C. For dry 




cure condition were tested at 1 hour or 24 hours post-mixing. Immediately prior to testing, 
the side faces of the cube were removed with a razor blade following pre-cut tabs, so that 
the cylinder was longitudinal between the top and bottom faces. The faces above and 
below the sample were compressed until failure, which appeared as a vertical crack as 
seen in figure 3. Tests were performed using an Instron Model 33R 4465 with a 5kN load 
cell. Samples were compressed at 1.5mm/min. Tests were stopped if the load reached 
above 1.6kN and dropped more than 1%. Amount of force (N) at failure was collected 
and used to calculate DTS in the equation: 
 
DTS = 2*Pmax/ (π*H*L), 
 
where Pmax = force at failure (N), H = 10mm, and L = 15mm. Five samples of each test 
antibiotic mix and control (no antibiotic mixed) MIIG® X3 in each condition (wet/dry, 







Figure 3: A. Before & B. After of Sample Being Compressed in DTS testing 
 
 
VII. Elution Testing: 
To simulate volumes used clinically and to ensure similar size and shape of bone 
graft specimens for elution testing, MIIG® X3 – 5cc was mixed with appropriate amount 
of antibiotics to keep same weight% as previously described and then injected into a 
silicone elastomer mold, 0.75 inch inner radius and 1 inch tall, and the top surface 
flattened with a spatula. The bolus appears as a much larger pellet, but the bolus was 
injected into the mold compared to a pellet being made by pouring the material over a 
silicone-molded plate and then removing excess with spatula.
30,47,48
 After allowing the 
samples to set for at least 10 minutes, they were removed from the mold and allowed to 
complete setting overnight under sterile vent hood. Each bolus was weighed to record 
mass before elution testing and then placed in 50 ml test tubes (one bolus per tube) with 




tubes with test and control boluses were placed in 37°C incubator to replicate body 
temperatures. The solution was changed on days 1, 2, 3, 5, 7, 14, 21, and 28; eluent 
samples from each time point were stored at -80°C. At the end of testing, remaining 
boluses were retrieved, allowed to dry overnight, and re-weighed to determine the 
amount of mass loss. 
The amount of antibiotics released from the bolus was measured via HPLC 
(Varian ProStar 325 system with UV-Vis Detector modules and Galaxie Chromatography 
software (v1.8.508.1)). Eluents were tested within 7 ± 1 days of being stored in the -80°C 
freezer and each antibiotic was tested separately. Table 1 contains information on the 
HLPC mobile and stationary phases, flow rates and detection wavelengths used for 
detecting the test antimicrobials. A calibration curve was obtained using known serial 
dilutions of the antibiotic in PBS; range was from ~10µg/mL - 2000µg/mL. The amount 
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It is noted that the HPLC method, including different mobile phases, used to 
determine concentrations of amphotericin B in test eluents was unsuccessful because of 
the insolubility of the drug in aqueous solutions. 
VIII. Turbidity Study 
A turbidity study was conducted using the eluents from the cefazolin and 
vancomycin containing calcium sulfate cement samples to determine activity of the 
released drugs to inhibit bacterial growth.  The Cowan I strain of S. aureus was used for 




was further diluted 1:5 in TSB before using it for inoculation. The turbidity testing 
scheme is outlined in Table 2. Each test for cefazolin and vancomycin had 3 positive 
controls (bacteria inoculum only), 3 negative controls (no bacteria or test eluents), and 7 
blank tubes that were used to ensure that the test eluent (PBS) did not contain anything 
that may interact with TSB and alter its absorbance. Eluents collected at each time point 
(7 time points) from test and control calcium sulfate samples (n=5) were evaluated.  
 
 
Table 2: Volume amounts of each liquid added to specific test tubes 










1.75mL 200µL X 50µL 
Negative 
Control 
1.80mL 200µL X X 
Blank Tubes 1.80mL X 200µL X 
Test Eluent 1.75mL X 200µL 50µL 




Since the minimum inhibition concentration (MIC) was not known for cefazolin 
in our lab, tests were conducted to determine the MIC for this S. aureus strain. The MIC 
tubes contained 1.75 mL of TSB, 200 µL of appropriate concentration of cefazolin, and 
50 µL of bacteria. The following serial dilutions were prepared in PBS and were further 




Table 3: Serial dilutions prepared for MIC - cefazolin 












As discussed in table 2 and 3, the tubes were prepared, capped, vortexed, and then 
they were incubated at 37°C overnight with the caps open. The next morning, each tube 
was vortexed again with caps closed and the turbidity measured based on absorbance at 
530nm using a spectrophotometer (Spectronic Instruments 20 Genesys). 
IX. Statistical Analysis 
 Statistical analysis was performed using Minitab Statistical Software (version 
14.20). For set time data, two-factor analysis of variance (ANOVA) was used to analyze 
the factors of type of set time performed and type of antibiotic used. For DTS data, 3 
factors were considered: time, antibiotic used, and curing conditions. For the XRD, 
elution, and dissolution, data was compared to the controls to determine if the results 




tests, data were further analyzed with the Tukey’s range test. Statistical significance was 





Chapter V: Results 
I. Set Time Testing 
The results of the set time testing of antibiotic-loaded calcium sulfate and controls 
using Vicat and Gilmore testers are shown in Figure 4. All set times took place between 
the range 7.25 min and 19.00 min. Bone grafts made with cefazolin took the shortest time 
to set in all 3 tests, while vancomycin took the longest to set. Gilmore 2 took on average 
between 5-8 extra minutes to set after Vicat/Gilmore 1 testing was complete. Vicat and 
Gilmore 1 results were very similar, with no more 0.12 minute difference between each 
other, but Vicat always had the faster set time in all 4 samples. Results of ANOVA 
identified that there were statistically significant differences between set times of calcium 
sulfate mixed with different antibiotics or control (p=0.0001) and there were difference in 
set time type of test (e.g. Vicat, Gilmore 1, and Gilmore 2) (p=0.0001). ANOVA 
indicated that there was a significant interaction between factors of antibiotic added and 
type of penetration test performed (p=0.0001). 
In general, Tukey’s range tests indicated that set times for each type of antibiotic 
added to the MIIG® X3 were greatest in Gilmore 2 tests as compared to Gilmore 1 and 
Vicat tests (p<0.001). For both the Vicat and Gilmore 1 tests, addition of cefazolin 
reduced set time the most, followed by control, amphotericin B and then vancomycin. In 
the Gilmore 2 test, the addition of cefazolin (p=0.0001) to the calcium sulfate still 
resulted in the fast set time, but there was no statistical differences between set times of 






Figure 4: Set time using Vicat & Gilmore testing apparatus of the antibiotic-loaded 
calcium sulfate bone grafts; statistical significant differences within test groups are 




II. Calcium Sulfate Conversion 
X-Ray Diffraction (XRD) results are shown in Figure 6. Intensity peaks at 
2θ=29.1 & 29.7 were used to calculate percentages of dihydrate and hemihydrate, 
respectively. The compositions were all very similar with only 1.75% difference between 









































statistically significant differences between dihydrate compositions of the calcium sulfate 

















Figure 6: Percent of hemihydrate & dihydrate present in each antibiotic-loaded & control 




III. Chemical Structure 
Infrared spectra from FTIR analysis are shown in Figures 7 (amphotericin B), 8 
(cefazolin), and 9 (vancomycin). In the figures, each sample has a comparison of the 
control and calcium sulfate accelerant below it. For each sample, there is a consistent 
peak at around 1100cm
-1
 wavenumbers, which is associated with the SO4 asymmetric 
stretch, and a smaller peak at 3500cm
-1
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hydrocarbons and other organic substances, to represent calcium sulfate peaks, which 
were expected. There are negligible variations between each IR spectrum, and the 
spectrums were very similar. 
 
 














Figure 8: IR spectrum of cefazolin-loaded MIIG® X3 sample 
 
 




IV. Surface Characteristics 
Images from the Scanning Electron Microscope (SEM) are shown in Figure 10 (A 
through H). The material set for over 72 hours and then fractured into smaller pieces with 
a hammer. The surface for each sample was very uneven and had many pores/holes. 
Crystalline structures between each sample looked similar, with no observable variations. 
From EDS analysis, oxygen had the highest weight% for each sample, followed by 
calcium, and then sulfur. The control bolus had the lowest wt% of oxygen at 55.8 ± 1.1% 
among the other bolus, but had the highest wt% of sulfur and calcium at 18.8 ± 0.58%. 






































Figure 10: SEM Images of internal structure of MIIG® X3 Bolus A. Amphotericin B-
loaded bolus (1500x w/EDS) B. Amphotericin B-loaded bolus (2500x) C. Cefazolin-
loaded bolus (1500x w/EDS) D. Cefazolin-loaded bolus (2500x) E. Vancomycin-loaded 
bolus (1500x w/EDS) F. Vancomycin-loaded bolus (2500x) G. Control bolus (1500x 
w/EDS) H. Control bolus (2500x) 
 
 
V. Mechanical Testing 
Results from the DTS testing of MIIG® X3 test and control samples in the wet 
and dry conditions are shown in Figure 11. Samples cured in FBS usually had a lower 
compressive strength than air cured samples, with the exception of amphotericin B and 
control samples. The highest diametral tensile strength was seen at 24hr/Air Cured with 
amphotericin B (18.54MPa), while the lowest diametral tensile strength was seen in the 
24hr/FBS Cured Control sample (8.40MPa). For 24hr/FBS cured, antibiotics improved 
diametral tensile strength above control. Results of ANOVA identified that there were 
statistically significant differences between Diametral tensile strength of calcium sulfate 
mixed with different antibiotics or control (p=0.0001) and there were difference in type 
of test (e.g. 1hr/Air Cured, 1hr/FBS Cured, 24hr/Air Cured, and 24hr/FBS Cured) 
(p=0.0001). ANOVA indicated that there was a significant interaction (p=0.0001).  
In general, Tukey’s range tests indicated that DTS values for each type of 
antibiotic added to the MIIG® X3 were greatest in 24hr/Air Cured tests as compared to 
1hr/Air Cured, 1hr/FBS Cured, and 24hr/FBS Cured (p=0.0001). Amphotericin B was 
significantly different than the other 2 antibiotics and control (p=0.0021). Cefazolin - 
vancomycin (p=0.9546) and vancomycin - control (p=0.0632) were significantly similar, 





Figure 11: Diametral tensile strength of antibiotic-loaded calcium sulfate bolus; 




VI. Elution Testing 
 The results of the HPLC determination of antibiotics in eluates from vancomycin 
and cefazolin-loaded calcium sulfate samples obtained from a 28 day study are shown in 
Figures 12 (daily release) and 13 (cumulative release). Antibiotic release was the highest 
on day 1 for both vancomycin and cefazolin at 1113.7 ± 38.8μg/mL and 2359.0 ± 
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released compared to vancomycin. After Day 1, cefazolin had a slightly higher release 
than vancomycin, except at Days 21 & 28. At Day 7, release was almost identical for 
both vancomycin and cefazolin at 518.9 ± 29.2μg/mL and 518.5 ± 49.1μg/mL, 
respectively, which were also both antibiotics’ lowest eluent concentrations. After 28 
days, 5680.4 ± 147.4μg/mL was released for vancomycin and 7074.8 ± 309.4μg/mL for 
cefazolin. Considering that 350mg of both antibiotics were added to a 5cc bolus, this 
gives us 70mg/mL of antibiotic added to the bolus. The amount of antibiotic released 
from each bolus was only 8.1% and 10.1% overall for vancomycin and cefazolin, 
respectively. When compared to the overall cumulative release, 19.6% of vancomycin 
was released on day 1 and 33.3% for cefazolin. Results of ANOVA showed that there 
were statistically significant differences between daily release concentrations of calcium 
sulfate mixed with different antibiotics or control (p<0.05). Tukey’s range test revealed 
that Day 1 was significantly different than all the other days (p<0.05). Days 3 & 7 






Figure 12: Elution behavior of sterile vancomycin and cefazolin-loaded calcium sulfate 
bolus in PBS at 37°C in a 28 day study. Daily release concentrations are shown. 









































Figure 13: Elution behavior of sterile vancomycin and cefazolin-loaded calcium sulfate 




VII. Dissolution Testing 
The results of the percent change in mass of the pellets during the elution tests are 
shown in Figure 14. The results were very similar, with only a 0.05g difference between 
highest and lowest dissolution averages. ANOVA identified that there were no 
statistically significant differences between percent mass change of calcium sulfate mixed 
















































Figure 14: Amount of dissolution during a 28 day elution testing for each antibiotic-




VIII. Turbidity study 
 The results for the determination of the MIC of cefazolin against the S. aureus in 
turbidity tests are shown in Fig 15. The minimum inhibition concentration (MIC) for 
cefazolin against S. aureus was less than 0.25μg/mL. Concentrations below 0.25μg/mL 
were not tested, so the exact MIC was not determined. The activity of the antibiotics in 



















Dissolution of Antibiotic-Loaded and Control 
Calcium Sulfate Bolus during Elution Testing




and cefazolin eluents, respectively. Eluents collected over the 28 day test period from 
both vancomycin and cefazolin-loaded calcium sulfate completely inhibited growth of 




Figure 15: Absorbance readings from minimum inhibition concentration (MIC) 
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Figure 16: Absorbance readings from turbidity study conducted on vancomycin-loaded 


























Figure 17: Absorbance readings from turbidity study conducted on cefazolin-loaded 


























Chapter VI: Discussion 
We investigated if MIIG® X3 may be used in local drug delivery with three 
different classes of antibiotics: amphotericin B (polyene antifungal), cefazolin (β-lactam 
antibacterial), and vancomycin (glycopeptide antibacterial). These antibiotics were 
chosen for their effectiveness against microbials that commonly cause osteomyelitis, 
especially S. aureus as well as S. epidermis and C. albicans. A major goal was to 
determine if the antibiotics would have any effect on the chemical reaction that converts 
hemihydrate to dihydrate, because a key aspect of loading antibiotic into calcium sulfate 
bone graft is to not hinder its mechanical strength. We tested physical properties with set 
time, calcium sulfate conversion with x-ray diffraction, chemical structure with Fourier 
transform infrared spectroscopy, surface characteristics with scanning election 
microscope, and mechanical strength with Diametral tensile strength test. We also sought 
to determine the elution of the antibiotics from the calcium sulfate bolus in phosphate 
buffered saline (PBS). Dissolution of the calcium sulfate bolus was analyzed to determine 
if antibiotic release was sufficient to inhibit bacterial growth. 
We found that the antibiotics cefazolin and vancomycin were easily incorporated 
into the MIIG® X3 kit by dissolving into the supplied water and then combining with 
calcium sulfate to form the bone graft. Amphotericin B did not dissolve completely in the 
supplied water for mixing the bone graft, because of its lower solubility; however, it was 
still able to be mixed. None of the evaluated antibiotics in this study prevented setting of 
the bone graft based on penetration tests or the conversion of hemihydrate to dihydrate as 




the type of antibiotic added to the MIIG® X3 cement, but it did not have an effect on the 
hemihydrate – dihydrate reaction or the dissolution rates. Statistical analyses 
demonstrated that cefazolin appeared to be the only antibiotic to be significantly different 
from the others on set time. Cefazolin caused the calcium sulfate to set approximately 31% 
faster compared to the control based from Gilmore 2 results, but not so quick that a 
physician could not use it for local drug delivery. Of course, a physician would need to be 
aware of this happening. Statistical analyses also showed that the addition of 
amphotericin B had a significant effect on the DTS of the bone grafts as compared to the 
other antibiotic and antibiotic free bone grafts. Addition of antibiotics to bolus appeared 
to have a slight improvement in DTS values over control samples in 1 hour/Air cured and 
24 hours/FBS cured conditions. FBS cured conditions, while still an in vitro test, are 
more representative of clinical applications when calcium sulfate is implanted into the 
body. These results suggest that addition of these three antibiotics have no real negative 
effects on the physical-chemical properties of the MIIG® X3 calcium sulfate bone graft. 
A study conducted by Bohner et al. shows that antibiotics may affect a bone 
graft’s tensile strength and setting time.
66
 Calcium phosphate pellets loaded with 
gentamicin, affected physical-chemical properties of the bone graft. Setting time 
increased from 2 to 4.5 minutes with 3% (w/w) gentamicin, but then slowly decreased to 
3.75 minutes as the amount of gentamicin was increased to 16% (w/w). Tensile strength 
increased from 0.4 to 1.6 MPa as the amount of gentamicin was increased to 16% (w/w). 
The Bohner study attributed these changes to the sulfate ions present in gentamicin, 
which induces a finer microstructure in the material. Even though this study used calcium 




similar. We may conclude by comparing previous studies and our study that adding 
antibiotic may have an effect on setting time and tensile strength, but conversion of 
hemihydrate to dehydrate is unaffected. 
Results from XRD and FTIR testing in our investigation showed that antibiotics 
did not have an overall effect on the chemical reaction of hemihydrate to dihydrate. FTIR 
charts for control and antibiotic-loaded MIIG® X3 appear very similar with little 
differences seen in the peaks. XRD results demonstrated that the compositions of 
dihydrate in antibiotic-loaded MIIG® X3 were almost identical to the controls. The 
dihydrate composition levels were between 90.1%-91.8%. A study by Doadrio et al. had 
similar results to our study.
25
 They conducted XRD and FTIR tests on their cephalexin-
loaded calcium sulfate pellets and concluded that the presence of cephalexin into the 
bone graft does not alter neither the physical-chemical behavior of the bone grafts nor 
produce structural changes on the pellets. Cephalexin is a cephalosporin antibiotic that is 
in the same class of antibiotic as cefazolin with very similar structures and mechanisms 
of action, therefore the Doadrio results are relevant to our study. A study by Jackson et al. 
demonstrated that vancomycin loaded into rapidly resorbing calcium sulfate pellets had a 
delayed release compared to the other two antibiotics, amikacin and gentamicin.
48 
They 
did not observe any significant differences in composition rates among the samples tested. 
Peaks at 2θ = 25° and 30° observed during XRD testing were tiny and indicated that very 
little hemihydrate was present. Results from our XRD study were similar to studies by 
Jackson et al. and Doadrio et al. of antibiotic-loaded calcium sulfate pellets and suggests, 
at least for the antibiotics evaluated, there is little effect of the antibiotics on the 




amounts increased with the addition of antibiotics compared to the control. The increase 
was very small, within 6%, and may be associated with the additional oxygen atoms that 
the antibiotics introduce into the mixture. 
Cefazolin and vancomycin had elution characteristics similar to previous studies 
where there was a typical burst release in day 1, but lower concentrations in later 
days.
22,30,48
 Cefazolin-loaded specimens released almost twice as much antibiotic as  the 
vancomycin-loaded specimens did initially and remained greater throughout the study. 
Daily release levels of vancomycin were more similar to cefazolin after day 14. Jackson 
et al. described calcium sulfate antibiotic elution from a pellet that dissolved within 24 
hours.
48
 Amikacin and gentamicin pellets fully dissolved within 12 hours, while 
vancomycin pellets released antibiotic all the way to 24 hours. Vancomycin had a spike 
in release at 1 hour and then another burst at 4 and 8 hours and then slowly decreased 
until it dissolved. They attributed this to vancomycin’s larger nine ring structure, as seen 
in Figure 18. This is further supported by data in this study; cefazolin’s smaller structure 







Figure 18: Comparison of cefazolin (left) and vancomycin (right) molecular structure; 
vancomycin’s larger structure slowed release from bolus 
 
 
Recovery rates of the antibiotics cefazolin and vancomycin were approximately 
10.1% and 8.1%, respectively. Heijink et al., reported 39% recovery of their vancomycin 
from OSTEOSET®, a calcium sulfate product also offered by Wright Medical.
24
 The 
higher percentages compared to our percentages may be contributed to the smaller pellets 
(~0.1cc/pellet) used in the OSTEOSET® kit; there is a higher surface area exposed to the 
PBS. In their study, they also mixed vancomycin with DBX, an allograft bone void filler 
made by Synthes (West Chester, PA), and Collagraft, a synthetic bone graft comprised of 
bovine collagen and hydroxyapatite/tricalcium phosphate (HA/TCP) granules made by 
Zimmer (Warsaw, IN). They were only able to retrieve 9% and 23%, respectively, of the 
vancomycin, which further supports that calcium sulfate is better suited for local drug 
delivery. Another study done by Udomkusonsri et al. showed that cefazolin-loaded 






 They only had a 24.10% recovery rate for cefazolin-loaded PMMA pellets. They 
believed calcium sulfate had a higher porosity which contributed to the higher antibiotic 
release. Their conclusion was that calcium sulfate may release antibiotic at a much higher 
concentration and be better in local drug delivery compared to PMMA. 
 By examining the statistical analysis, we may conclude that the dissolution rates 
were similar among the 4 test groups: control, amphotericin B, cefazolin, and 
vancomycin.  Dissolution results were not indicative of previous studies conducted with 
antibiotic-loaded calcium sulfate pellets. In a study conducted by Richelsoph et al., 
daptomycin and tobramycin were mixed with calcium sulfate and dissolution and elution 
rates were measured in saline.
67
 They discovered that the daptomycin-loaded pellets 
dissolved more rapidly than tobramycin-loaded pellets. Dissolution of the calcium sulfate 
material appeared to be dependent on the antibiotic. In our case, there was no difference 
in dissolution with the 3 antibiotics, which was different than Richelsoph et al. A 
comparison between our dissolution results and Richelsoph’s results would be biased. 
Richelsoph used much smaller pellets, while our study used a bolus; surface areas would 
be very different. Overall, we may conclude that dissolution rates are dependent on the 
chemical properties of the antibiotic used, such is the case with the study conducted by 
Bohner et al. and the extra sulfate ions produced from the gentamicin added.
66
 
 Cytotoxicity to osteoblasts is a concern with the higher concentrations of 
antibiotic. A study conducted by Edin et al. tested the effects of cefazolin and 
vancomycin on osteoblast-like cells.
23
 They used MG-63 human osteosarcoma cell line 
and exposed it to different concentrations of the antibiotics ranging between 0-




determined that levels of 1000µg/mL or less for vancomycin and 100µg/mL or less for 
cefazolin have little or no effect on the cells. But concentrations of 10,000µg/mL for 
vancomycin and cefazolin caused cell death. Levels of 200µg/mL for cefazolin did cause 
significant decrease in cell replication. They concluded that vancomycin is less toxic than 
cefazolin at higher concentrations and may be a better antibiotic for local drug delivery. 
The highest concentrations for vancomycin were seen on Day 1 (1113.7 ± 38.8µg/mL), 
which were significantly below the 10,000µg/mL level. Highest concentrations for 
cefazolin were also seen on Day 1 (2359.0 ± 106.3µg/mL) and were below 10,000µg/mL 
level, but higher than the 200µg/mL level that may cause significant decreases in 
osteoblastic cell replication. After day 1, cefazolin concentrations were less than the 
200µg/mL and may not affect cell proliferation. This would certainly have to be 
considered by a physician planning on administering cefazolin though local drug delivery. 
From our results in the turbidity study conducted, S. aureus was inhibited from growing 
even at the lowest concentrations 518.5 ± 49.1µg/mL at Day 7. The MIC for cefazolin 
was determined to be lower than 0.25µg/mL, therefore a lower concentration of cefazolin 
may be considered in future studies.  In a separate study conducted by Sealy et al., they 
loaded amphotericin B into hydroxyapatite, PMMA, and beta-tricalcium phosphate 
beads.
68
 The released concentrations were between 1.75 and 2.0µg/mL over 110 days for 
all the beads. In the Sealy study, amphotericin B-loaded pellets were determined to be not 
toxic to osteoblasts during 72 hours of exposure in tissue culture medium. 
The insolubility of amphotericin B prevented us from determining concentration 
and release rates with the high performance liquid chromatography (HPLC). 




dimethyl sulfoxide. These solvents were added to test eluents before running the HPLC, 
but we were still unsuccessful in measuring the amount of amphotericin B. A concern we 
have is that the amphotericin B’s antibiotic level was relatively low in the calcium sulfate 
bolus formulation, because of its toxicity within the body and as such concentrations in 
eluents may also be low. Serial concentrations for standard curves went as low as 
5µg/mL, and were detected by HPLC, but HPLC still did not detect any antibiotic within 
eluents. If all the antibiotic was released in day 1, concentration levels would be almost 
3,400µg/mL and would have been high enough to detect. Replacing PBS with one of the 
solvents was considered, but deemed impractical and unrealistic in a clinical aspect. An 
alternate spectrophotometric detection method for amphotericin B was tried to measure 
concentrations in the eluents, but also was unsuccessful. A third biologically based 
method based on zone of inhibition may provide a means to estimate released 
amphotericin B’s concentrations, if any antibiotics were even released. The test would 
use C. albicans as the microorganism since amphotericin B is used to treat fungal 
infections. The fungus will be grown on an agar plate over 48 hours. Paper disks 
saturated with the eluent would be placed on the plate and if the antibiotic is still 
functional, it will create an inhibited zone around the disk. By measuring this zone of 
inhibition and comparing it to zones around known concentrations of amphotericin B on 
saturated disks, concentration of amphotericin B in the eluent may be estimated. These 
experiments are planned to be conducted with Dr. Courtney at the VA Hospital, Memphis, 
TN, in the near future. 
In the turbidity study conducted on cefazolin and vancomycin eluents with S. 




entire 28 day period of the study. In these studies, we may only conclude that the bacteria 
were inhibited from growing, but not eliminated. From our results, we may state that 
bacteria growth was inhibited by almost ~98% compared to positive controls. 
Udomkusonsri et al. also tested the cefazolin eluents effectiveness against Bacillus 
subtilis, another Gram-positive bacteria.
27
 Eluents inhibited the bacteria’s growth 
successfully and they determined that mixing cefazolin with calcium sulfate would not 
affect cefazolin’s antibacterial activity. Comparisons can still be made between our study 
and referenced studies, since the amount of pellets packed into a bone void is almost 
equivalent to a 5cc bolus. However, there are not many studies available using a larger 
bolus as our study used. At the end of the 28 day elution study, a great amount of bolus 
and antibiotic remained. Inhibition of bacterial growth was seen all the way to the end, 
which leads us to believe that the bolus may be used for extended amounts of protection, 
perhaps up to 3-4 months. Of course biofilm formation is a concern, but if antibiotic level 
is high enough, then it may combat the biofilm development. 
In vivo studies have been conducted with antibiotic-loaded calcium sulfate 
pellets.
26,29,38,40,48
 A study conducted by Xie et al. compared vancomycin-loaded calcium 
sulfate to vancomycin-loaded borate glass.
26
 They infected 65 rabbits with methicillin-
resistant S. aureus (MRSA) and split them into 4 groups. Each rabbit received treatment 
by debridement and the void was filled with: nothing (group 1), pure borate glass (group 
2), vancomycin-loaded calcium sulfate (group 3), and vancomycin-loaded borate glass 
(group 4). The vancomycin-loaded calcium sulfate and borate glass had the best results 
against the MRSA with 73.33% and 81.25% kill rates, respectively. It was observed that 




glass only being partially reabsorbed. Even though antibiotic levels were different from 
our study, it is still important to verify that calcium sulfate may be used as a local drug 
delivery system successfully. Richelsoph et al. conducted an in vivo study involving adult 
Spanish-Boer goats implanted with amikacin-loaded calcium sulfate and PMMA beads.
48
 
The amikacin-loaded calcium sulfate beads sufficiently reduced bacterial growth than 
amikacin-loaded PMMA beads. Levels of antibiotics released in these studies were above 
the MIC of the infecting microbial, which was similar to our study with antibiotic release 
being higher than MIC of S. aureus. From these referenced studies we may conclude that 






Chapter VII: Conclusions 
Aims of this study were to characterize effects of mixing one of the three 
antibiotics, amphotericin B, cefazolin, and vancomycin, on physical, chemical, and 
mechanical properties of MIIG® X3. The properties evaluated were set time, phases, 
chemistry, and morphology via Vicat and Gilmore penetration tests, X-Ray Diffraction 
(XRD), Fourier Transform Infrared Spectroscopy (FTIR), and Scanning Election 
Microscope (SEM), respectively. Diametral Tensile Strength (DTS) was also performed 
to provide information on mechanical strength.  The in vitro release of the antibiotics 
from clinically relevant bolus samples of injectable material over 28 days in saline 
solution using High Performance Liquid Chromatography (HPLC) techniques was 
measured. The dissolution of the bolus by evaluated for mass change during the 28 day 
elution study was also determined. Finally, the ability of the released antibiotics to inhibit 
the in vitro growth of representative microbes associated with osteomyelitis was 
evaluated. Based on the result of this work we conclude that: 
 Mixing of amphotericin B, cefazolin, and vancomycin with MIIG® X3 calcium 
sulfate did not adversely affect set times, chemical or physical structure, 
mechanical properties, or degradation times as compared to antibiotic free 
formulation. Bolus will still set as normal MIIG® X3 and will still remain strong 
enough to be used in non-load bearing fracture fixation or as bone void filler. 
 MIIG® X3 loaded with cefazolin and vancomycin was able to release the 
antibiotics at levels that inhibited in vitro growth of S. aureus, a model pathogen, 




 These results suggest that calcium sulfate cements may be used to locally delivery 
vancomycin and cefazolin antibiotics to treat/prevent osteomyelitis. 
 Release of amphotericin B from calcium sulfate could not be determined in this 




Chapter VIII: Future Work 
This preliminary investigation provided basic information on the effects of the 
antibiotics, amphotericin B, cefazolin, and vancomycin, on the physical and chemical 
characteristics of injectable calcium sulfate bone graft and on levels and antibacterial 
properties of released vancomycin and cefazolin in vitro. Future research is needed to 
address additional important questions. Since release levels of amphotericin B were not 
determined, a biological based semi-quantitative zone of inhibition assay using C. 
albicans may be useful to estimate the release amount and activity of amphotericin B. 
Alternatively, other more soluble forms of amphotericin B may utilized that would 
provide amounts of the released antibiotic that could be detected and that would have 
antimicrobial properties.  
Another interesting possibility would be to load MIIG® X3 with growth factors, 
anti-inflammatory and anti-cancer drugs, or painkillers and to evaluate effects on cement 
and ability of cement to delivery agents locally. There have been previous studies already 
conducted incorporating these drugs, and it was discovered that they had no physical-
chemical effect on the calcium sulfate.
20,21
 Mixing different types of antibiotics is also a 
possibility and may be tested by using the series of analysis that our study utilized. 
Mixing one antibiotic effective against Gram-negative bacteria and another one effective 
against Gram-positive bacteria would help combat multiple microorganisms at once, 
since osteomyelitic infections may be caused by two or more bacteria. Increasing dosages 




study to be performed before implantation. Cytotoxicity studies were not performed in 
our study and would further answer any questions that may remain.  
One of the most important inquiries is the materials effectiveness in in vivo tests. 
It would be interesting to observe how this material performs in animal studies or even 
clinical studies. Another concern would be how long would it take for the bolus to 
completely dissolve and if it would consistently release high concentrations of antibiotic 
all the way till the end. If the bolus is able to release antibiotics at a high enough 
concentration that keeps it above the microorganism’s MIC, then it may remain effective. 
But if the bolus takes some time to dissolve and antibiotic release is low, then biofilm 
formation could become a problem. Biofilm formation tests would be beneficial in this 
study to discover if biofilm is a concern when using a large bolus. If biofilm forms on the 
surface of the bolus, then it would need to be removed, since eradication of biofilm is 
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Table 4: Set time of antibiotic-loaded calcium sulfate bolus 
 Amphotericin B Cefazolin Vancomycin Control 
Mean ± Std. Dev (min.) 
Vicat 10.58 ± 0.43 8.10 ± 0.84 11.81 ± 0.69 9.48± 0.26 
Gilmore 1 10.66 ± 0.43 8.17 ± 0.83 11.90 ± 0.71 9.60 ± 0.32 




Table 5: Composition of antibiotic-loaded and control calcium sulfate bolus thru XRD 
testing 
 Amphotericin B Cefazolin Vancomycin Control 
Mean ± Std. Dev. 
Intensity at 2θ=29.1 1796 ± 307 1704 ± 647 1625± 265 1335 ± 342 
Intensity at 2θ=29.7 169 ± 28 154 ± 46 177 ± 27 116 ± 22 
Dihydrate (%) 91.2 ± 2.5 91.3 ± 1.9 90.1 ± 1.3 91.8 ± 1.2 




Table 6: Diametral tensile strength at fracture for each drug in either Fetal Bovine Serum 
(FBS) or air 
 Amphotericin B Cefazolin Vancomycin Control 
Mean ± Std. Dev (MPa) 
1 Hour & Air Dried 10.31 ± 0.21 9.43 ± 0.67 9.40 ± 0.16 9.10 ± 0.61 
1 Hour & FBS Dried 10.71 ± 0.44 9.19 ± 0.47 8.91 ± 0.48 10.27 ± 0.96 
24 Hour & Air Dried 18.54 ± 1.07 10.90 ± 0.77 11.90 ± 0.54 16.08 ± 1.18 
24 Hour & FBS 
Dried 




Table 7: Elution behavior of sterile vancomycin and cefazolin-loaded calcium sulfate 
bolus in a 28 day study 
Day Vancomycin Cefazolin 
Daily Release Concentration (μg/mL) 




Mean ± Std. Dev. Coefficient of 
Variation (%) 
1 1113.70 ± 38.81 3.49 2358.96 ± 106.29 4.51 
3 822.62 ± 23.22 2.82 1019.84 ± 102.26 10.03 
5 624.15 ± 18.56 2.97 685.98 ± 67.19 9.79 
7 518.89 ± 29.20 5.63 518.53 ± 49.10 9.47 
14 834.94 ± 10.29 1.23 1055.89 ± 98.49 9.33 
21 891.36 ± 29.53 3.31 795.99 ± 60.52 7.60 
28 718.77 ± 33.63 4.68 639.56 ± 37.85 5.92 
Cumulative Release Concentration (μg/mL) 




Mean ± Std. Dev. Coefficient of 
Variation (%) 
1 1113.70 ± 38.81 3.49 2358.96 ± 106.29 4.51 
3 1936.32 ± 61.62 3.18 3378.80 ± 161.44 4.78 
5 2560.47 ± 73.71 2.88 4064.78 ± 203.49 5.01 
7 3079.36 ± 94.55 3.07 4583.31 ± 243.73 5.32 
14 3914.30 ± 100.82 2.58 5639.20 ± 316.54 5.61 
21 4805.67 ± 120.68 2.51 6435.19 ± 362.07 5.63 





Table 8: Dissolution of antibiotic-loaded and control calcium sulfate pellets during a 28 
day elution test 
 Amphotericin B Cefazolin Vancomycin Control 
Mean ± Std. Dev. 
Initial Weight (g) 10.22 ± 0.16 10.30 ± 0.22 10.23 ± 0.16 10.30 ± 0.12 
Final Weight (g) 9.75 ± 0.13 9.85 ± 0.21 9.75 ± 0.20 9.81 ± 0.12 
Total Dissolution (g) 0.47 ± 0.07 0.44 ± 0.11 0.48 ± 0.07 0.49 ± 0.07 




Table 9: Turbidity study of cefazolin and vancomycin-loaded calcium sulfate bolus 
against Staphylococcus aureus Cowan I 
 Vancomycin Cefazolin 
Absorbance @ 530nm 
Mean ± Std. Dev. 
Blank 0.012 ± 0.003 0.000 ± 0.002 
Negative Control 0.004 ± 0.005 0.022 ± 0.001 
Positive Control 0.964 ± 0.021 0.967 ± 0.027 
Control - Day 1 0.965 ± 0.029 
Control - Day 3 0.957 ± 0.023 
Control - Day 5 0.939 ± 0.018 
Control - Day 7 0.958 ± 0.023 
Control - Day 14 0.958 ± 0.037 
Control - Day 21 0.932 ± 0.021 
Control - Day 28 0.965 ± 0.049 
Day 1 0.019 ± 0.002 0.022 ± 0.001 
Day 3 0.020 ± 0.002 0.021 ± 0.002 
Day 5 0.021 ± 0.004 0.020 ± 0.001 
Day 7 0.021 ± 0.004 0.021 ± 0.001 
Day 14 0.022 ± 0.002 0.018 ± 0.006 
Day 21 0.023 ± 0.002 0.020 ± 0.001 
Day 28 0.020 ± 0.003 0.021 ± 0.001 
MIC - 16 μg/mL  0.011 ± 0.013 
MIC - 8 μg/mL 0.011 ± 0.013 
MIC - 4 μg/mL 0.012 ± 0.007 
MIC - 2 μg/mL 0.012 ± 0.002 
MIC - 1 μg/mL -0.001 ± 0.001 
MIC - 0.5 μg/mL -0.003 ± 0.001 
MIC - 0.25 μg/mL -0.002 ± 0.000 
MIC - 0 μg/mL 0.924 ± 0.028 
 
